Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study - Wikidata - awgldk - TriplyDB

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

http://www.wikidata.org/entity/Q28216693

about

sameAs

A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial Evaluating and treating cardiometabolic risk factors: a case discussion Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients JTT-705: is there still future for a CETP inhibitor after torcetrapib?The therapeutic role of niacin in dyslipidemia management Drug off-target effects predicted using structural analysis in the context of a metabolic network model Human apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changes Structural features of cholesteryl ester transfer protein: a molecular dynamics simulation study The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.Screening the human serum proteome for genotype-phenotype associations: an analysis of the IL6 -174G>C polymorphism.Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.Homeostasis of free cholesterol in the blood: a preliminary evaluation and modeling of its passive transport.The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP).Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.Raising HDL cholesterol in women.Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.Emerging drugs for hyperlipidemia.Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.New lipid-modifying therapies.Seven functional polymorphisms in the CETP gene and myocardial infarction risk: a meta-analysis and meta-regression Molecular regulation of HDL metabolism and function: implications for novel therapies.Pathophysiology of dyslipidaemia in the metabolic syndrome.Pharmacotherapy for dyslipidaemia--current therapies and future agents.Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins.New lipid-lowering agents.HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular disease.Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.Novel HDL-directed pharmacotherapeutic strategies.Lipid-lowering therapies in development.

P2860

Q23913851-77461658-47E4-4DDD-BFB9-C8E0CB8F70B8 Q24323992-99EA03EB-BC97-4D2A-A59A-207FC731A080 Q24624286-6627EAAD-67AA-4532-A2BB-031E33127778 Q24648125-ECAF6325-CFA1-4EBB-A0AE-BB7E23134E24 Q28196750-B53DB087-F1A7-44FD-A768-0BD5AA66B49C Q28200554-3525BEC9-FB65-4F44-8705-7942FD0B50CD Q28285064-7866677F-C677-4F86-BD2E-92847F3C62FA Q28294281-8D672A81-98B9-45BE-9528-77DCA6CC35CB Q28294797-D2D8DBD2-EB89-469E-90F0-DCD3367D4864 Q28304559-E2D176A0-757A-4B00-8D6E-F3D21CED4EAA Q28475693-4164C44B-8082-4000-97FA-709E3C7BA0D1 Q28570515-3CB3F8E9-E203-4E5B-9FCF-F42B00FD6E3B Q30155210-9B6438FA-9D0C-418B-8A54-D9ECAE19BA20 Q30380628-FDE14283-A063-4232-92D0-82AAB9256E33 Q33274516-73C07760-108C-42CC-B6A7-5DA2DB88A609 Q33569541-3ED09533-1ED9-4C9C-9FD2-E3DE7A0FB326 Q33590777-5DD41CFA-5D23-4843-9546-1B7CA58106AB Q33639433-5A2673C1-4C6E-48A8-8AFD-4437E1957996 Q33653598-511F885E-B66E-4DBC-8030-324D1B010C48 Q33993233-D78FCFC0-AA70-428C-A648-6BAFE3D5E128 Q34155049-90B0E296-B785-4779-BFDF-3D91720DDF25 Q34220871-64ADD31C-9511-429D-9977-CEB3458F635F Q34253290-C876094A-8189-4B23-9BE6-D640C2156E4A Q34271942-C25E71A6-A0D0-4F56-86BC-9F4D3B49D7D4 Q34441411-BC7EFF83-89B6-4146-B3B3-53E42718C446 Q34559971-5A26BED3-020C-456C-8D2B-E869011D5736 Q34619115-DE6EFB2B-54A7-4ECC-B90A-BF09D830DD33 Q35034986-CA43292F-BD57-48EC-A8B9-286DEBDF532F Q35073322-9D3EF08B-4138-4BFF-8E0C-D220821F1144 Q35095291-2013D2BB-7EA0-4E66-8C11-C9186B7AD5EB Q35191066-0515417F-708F-443C-B56A-B566E77B9B89 Q35522107-7CBA819F-C781-4B1A-A36C-DB0596A1F8CB Q35574960-F75C8CC9-A04F-4ACF-B5F5-96B5D3729AF0 Q35590298-6F60A8F9-D7EA-4FF2-92C3-6FCFA110A4F7 Q35592465-BB5E78B4-3DFE-4E42-BFCB-8C7A86B3AF7B Q35602647-50834FDE-4AE4-4C5F-8C60-3C4B1BC54615 Q35754375-155D4E5C-CF55-41CD-821E-DB8CE9DC72BE Q35836143-49E5AAA2-B9DC-4C01-8E13-D2ED3847D258 Q35860020-0DAE20F1-916E-4F1B-B5D0-96083E5A4B67 Q35925570-5FBBE139-88E2-4346-9433-E8308C862529

P2860

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

http://www.wikidata.org/entity/Q28216693

description

2002 nî lūn-bûn

@nan

2002 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Efficacy and safety of a novel ...... d phase II dose-response study

@ast

Efficacy and safety of a novel ...... d phase II dose-response study

@en

Efficacy and safety of a novel ...... d phase II dose-response study

@nl

type

label

Efficacy and safety of a novel ...... d phase II dose-response study

@ast

Efficacy and safety of a novel ...... d phase II dose-response study

@en

Efficacy and safety of a novel ...... d phase II dose-response study

@nl

prefLabel

Efficacy and safety of a novel ...... d phase II dose-response study

@ast

Efficacy and safety of a novel ...... d phase II dose-response study

@en

Efficacy and safety of a novel ...... d phase II dose-response study

@nl

P1433

Q28216693-5A395C7A-0B4F-437F-A292-412F11C70C8C

P1476

Q28216693-82641525-7515-4D91-B5DB-8D4303DB0979

P2093

Q28216693-237F4044-A1E8-45A3-A089-24BB80E87DB3

Q28216693-24D2ABB3-EE9D-44EC-88DA-31E5EE47E5AF

Q28216693-35D02EB0-C155-40D4-9DE3-90CDAD6E20B1

Q28216693-421034AC-810B-481F-931A-BCB50BA89165

Q28216693-510078EC-30EB-4ACD-A777-898838567A9E

Q28216693-6097EAD6-45F3-4DB5-BBF5-BE042E51216B

Q28216693-70436C16-0540-4EA6-9458-273D144600A8

Q28216693-E683164F-3ED8-49C5-B9E8-57974DBDF392

P304

Q28216693-0302605B-E298-413A-8319-98665BCCDE1D

P31

Q28216693-4855D1D5-0C8B-47F5-80B3-84DF115789FF

P3181

Q28216693-62BB37CF-D65C-48D2-8703-BE40AFEB55A4

P356

Q28216693-5EA354EB-5236-44CA-8786-AE839FAD353C

P407

Q28216693-AA529C3D-B10F-4C12-8AE6-35881CE5B557

P433

Q28216693-A35C55E3-DB4A-4A8F-ACC0-E71F58E27BD8

P478

Q28216693-489BE896-100C-40B2-960F-F1C768E11F8F

P577

Q28216693-9EF090D9-98E2-4BFA-9B2D-8EE144E9AC34

P698

Q28216693-1970CF88-74D3-4ED4-BF7B-8F40B919E73D

P3181

P356

01.CIR.0000015857.31889.7B

P1433

P1476

Efficacy and safety of a novel ...... d phase II dose-response study

@en

P2093

Aeilko H Zwinderman

http://www.w3.org/2001/XMLSchema#string

Anton F H Stalenhoef

http://www.w3.org/2001/XMLSchema#string

Arie van Tol

http://www.w3.org/2001/XMLSchema#string

Greetje J de Grooth

http://www.w3.org/2001/XMLSchema#string

Jacqueline de Graaf

http://www.w3.org/2001/XMLSchema#string

Jan Albert Kuivenhoven

http://www.w3.org/2001/XMLSchema#string

Jan L Posma

http://www.w3.org/2001/XMLSchema#string

John J P Kastelein

http://www.w3.org/2001/XMLSchema#string

P304

2159-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4849613

http://www.w3.org/2001/XMLSchema#string

P356

10.1161/01.CIR.0000015857.31889.7B

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2002-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11994249

http://www.w3.org/2001/XMLSchema#string